Results 101 to 110 of about 2,198 (193)
FDA Approves Pralsetinib for Treatment of Adults with Metastatic RET Fusion-Positive NSCLC [PDF]
ONCOLOGY, 2020 The US FDA granted accelerated approval to pralsetinib for the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer.
openaire +2 more sources
Cancer Medicine, Volume 14, Issue 4, February 2025.NRTK+ and RET+ CRC possess significantly higher TMB than other RTK+ CRC or NTRK+/RET+ non‐CRC solid tumors. TMB testing should be routinely done in MSI‐H CRC and where TMB > 35 mut/MB samples should be screened for NTRK and RET fusions as an enrichment strategy to provide an additional treatment option for NTRK+ and RET+ CRC patients.
Zhaohui Liao Arter +3 more
wiley +1 more source
State of the Art in 3D Culture Models Applied to Thyroid Cancer [PDF]
Thyroid cancer (TC) is the prevalent endocrine tumor with a rising incidence, particularly in higher-income countries, leading to an increased interest in its management and treatment.
Matrone A., Plebani R., Prete A.
core +1 more source
RET-mutated non-small cell lung cancer treated with pralsetinib: a case series
, 2022 Alessandro Galletti +8 more
openalex +1 more source
RET Fusion-Positive Non-small Cell Lung Cancer: The Evolving Treatment Landscape [PDF]
, 2023 Califano, Raffaele +4 more
core +1 more source
Adaptive Darwinian Off-Target Resistance Mechanisms to Selective RET Inhibition in RET Driven Cancer. [PDF]
Patients treated with RET protein tyrosine kinase inhibitors (TKIs) selpercatinib or pralsetinib develop RET TKI resistance by secondary RET mutations or alterative oncogenes, of which alterative oncogenes pose a greater challenge for disease management ...
Amini, Behrang +12 more
core +1 more source
Demographic profiles of clinical research participants in FDA-approved NMEs [PDF]
, 2022 Drug development is a rigorous and expensive process that takes between 10 and15 years. Recruitment and retention of human subjects in clinical trials is challenging.
Ojetayo, Abayomi Oladoye
core +1 more source
OA05.02 Analysis of Resistance Mmechanisms to Pralsetinib in Patients with RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC) from the ARROW Study [PDF]
, 2021 Justin F. Gainor +7 more
openalex +1 more source
Radioiodine-refractory thyroid cancer: a complex challenge [PDF]
, 2021 Barrea, Luigi +3 more
core +1 more source